PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19782127-4 2010 Cellular release of IL-1alpha, IL-1beta and IL-6 was significantly attenuated by curcumin and by inhibitors of the MAPKs ERK1/2 (PD98069), p38 (SB202190) and JNK (SP600125), whereas pyrrolidine dithiocarbamate (PDTC) attenuated the release of IL-6, but not of IL-1alpha and IL-1beta. pyrrolidine dithiocarbamic acid 182-209 interleukin 6 Rattus norvegicus 44-48 25412187-7 2015 In addition, pre-treatment of the cells with NaHS or PDTC ameliorated the HG-induced inflammatory response, leading to a decrease in the levels of IL-1beta, IL-6 and tumor necrosis factor-alpha (TNF-alpha). pyrrolidine dithiocarbamic acid 53-57 interleukin 6 Rattus norvegicus 157-161 24663080-7 2014 Finally, pyrrolidine dithiocarbamate also reduced the levels of IL-6 and TNF-alpha and the activation of NF-kappaB. pyrrolidine dithiocarbamic acid 9-36 interleukin 6 Rattus norvegicus 64-68 22972875-9 2012 Pyrrolidine dithiocarbamate inhibited nuclear localization of NF-kappaBp65 and subsequent downregulation of the transcription and secretion of TNF-alpha and IL-6. pyrrolidine dithiocarbamic acid 0-27 interleukin 6 Rattus norvegicus 157-161 19782127-4 2010 Cellular release of IL-1alpha, IL-1beta and IL-6 was significantly attenuated by curcumin and by inhibitors of the MAPKs ERK1/2 (PD98069), p38 (SB202190) and JNK (SP600125), whereas pyrrolidine dithiocarbamate (PDTC) attenuated the release of IL-6, but not of IL-1alpha and IL-1beta. pyrrolidine dithiocarbamic acid 211-215 interleukin 6 Rattus norvegicus 44-48 23807148-6 2013 The inhibition of NF-kappaB by pyrrolidine dithiocarbamate (PDTC), a selective inhibitor of NF-kappaB, significantly ameliorated DOX-induced inflammation, leading to a decrease in the levels of IL-1beta and IL-6, as well as TNF-alpha production in H9c2 cells. pyrrolidine dithiocarbamic acid 31-58 interleukin 6 Rattus norvegicus 207-211 23807148-6 2013 The inhibition of NF-kappaB by pyrrolidine dithiocarbamate (PDTC), a selective inhibitor of NF-kappaB, significantly ameliorated DOX-induced inflammation, leading to a decrease in the levels of IL-1beta and IL-6, as well as TNF-alpha production in H9c2 cells. pyrrolidine dithiocarbamic acid 60-64 interleukin 6 Rattus norvegicus 207-211 33380567-11 2021 TAK242 or NF-kappaB inhibitor pyrrolidinedithiocarbamic acid alleviated mechanical and thermal pain behaviors, inhibited spinal microglia activation, moderated spinal inflammatory response manifested by decreasing interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha expression and increasing IL-10 expression in the spinal dorsal horn. pyrrolidine dithiocarbamic acid 30-60 interleukin 6 Rattus norvegicus 238-242 16815050-9 2006 Pyrrolidine dithiocarbamate (PDTC) suppressed Hcy-induced IL-6 release, a finding compatible with involvement of reactive oxygen species as second messengers in cytokine production mediated by Hcy. pyrrolidine dithiocarbamic acid 0-27 interleukin 6 Rattus norvegicus 58-62 16815050-9 2006 Pyrrolidine dithiocarbamate (PDTC) suppressed Hcy-induced IL-6 release, a finding compatible with involvement of reactive oxygen species as second messengers in cytokine production mediated by Hcy. pyrrolidine dithiocarbamic acid 29-33 interleukin 6 Rattus norvegicus 58-62 15954894-13 2005 Pretreatment of the cells with NF-kappaB inhibitor pyrrolidine dithio-carbamate (PDTC) blocked the productions of IL-1beta, IL-6, and activation of NF-kappaB induced by TNF-alpha. pyrrolidine dithiocarbamic acid 51-79 interleukin 6 Rattus norvegicus 124-128 15954894-13 2005 Pretreatment of the cells with NF-kappaB inhibitor pyrrolidine dithio-carbamate (PDTC) blocked the productions of IL-1beta, IL-6, and activation of NF-kappaB induced by TNF-alpha. pyrrolidine dithiocarbamic acid 81-85 interleukin 6 Rattus norvegicus 124-128 16871588-7 2006 Inhibition of p38 and NF-kappaB activation by SB203580 and pyrrolidine dithiocarbamate, respectively, blocked endotoxin-induced H(2)O(2), NO, TNF-alpha, and IL-6 synthesis. pyrrolidine dithiocarbamic acid 59-86 interleukin 6 Rattus norvegicus 157-161 32116790-7 2020 Chronic treatment with the NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC), prevented activation of renal TLR4, NF-kappaB or IL-6, without interfering with blood glucose. pyrrolidine dithiocarbamic acid 48-75 interleukin 6 Rattus norvegicus 133-137 32848796-7 2020 Furthermore, pyrrolidinedithiocarbamate (PDTC, a selective inhibitor of NF-kappaB p65) not only alleviated the OGD/R-induced HBMVECs injury and permeability, but also reduced the expression of TNF-alpha, IL-6, IL-1beta, p-p65, and p-IkappaB, and the protective effect of PDTC was equivalent to that of TPPU. pyrrolidine dithiocarbamic acid 13-39 interleukin 6 Rattus norvegicus 204-208 32848796-7 2020 Furthermore, pyrrolidinedithiocarbamate (PDTC, a selective inhibitor of NF-kappaB p65) not only alleviated the OGD/R-induced HBMVECs injury and permeability, but also reduced the expression of TNF-alpha, IL-6, IL-1beta, p-p65, and p-IkappaB, and the protective effect of PDTC was equivalent to that of TPPU. pyrrolidine dithiocarbamic acid 41-45 interleukin 6 Rattus norvegicus 204-208 32116790-7 2020 Chronic treatment with the NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC), prevented activation of renal TLR4, NF-kappaB or IL-6, without interfering with blood glucose. pyrrolidine dithiocarbamic acid 77-81 interleukin 6 Rattus norvegicus 133-137 30468489-12 2018 The levels of TNF-alpha, IL-1beta, IL-6 and IL-8 in PDTC group were significantly lower than in OL group (p<0.05). pyrrolidine dithiocarbamic acid 52-56 interleukin 6 Rattus norvegicus 35-39 27959400-10 2017 Pretreatment of the in vitro resistin-treated AP model with the NF-kappaB inhibitor, pyrrolidine dithiocarbamate decreased the protein expression of the NF-kappaB p65 subunit in nuclei, and significantly attenuated the increased mRNA expression levels of TNF-alpha and IL-6 induced by resistin. pyrrolidine dithiocarbamic acid 85-112 interleukin 6 Rattus norvegicus 269-273